Caption Management’s ProQR Therapeutics PRQR Stock Holding History

Caption Management’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,065,300	Closed	-$964K	–	1750
2022 Q1	$964K	Buy	+1,065,300	New	+$3.57M	0.01%	987
2021 Q4	–	Sell	-50,300	Closed	-$421K	–	1861
2021 Q3	$421K	Buy	+50,300	New	+$329K	﹤0.01%	1236

Other funds holding PRQR

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Caption Management's PRQR Position: Q2 2022 in Review

Caption Management sold out of ProQR Therapeutics (PRQR) in Q2 2022, closing a stake of 60,000 shares — an estimated $55K sold.

Caption Management first reported a position in PRQR in Q1 2022 and held it in 1 quarter. The position peaked at $55K in Q1 2022. 51 funds tracked by Wall St. Rank hold PRQR as of Q2 2022.

Caption Management reported no remaining ProQR Therapeutics position as of Q2 2022 after selling out during the quarter.
Caption Management sold 60,000 ProQR Therapeutics shares in Q2 2022, an estimated $55K.
Caption Management first reported a position in ProQR Therapeutics in Q1 2022 and held it in 1 quarter.
Caption Management's ProQR Therapeutics position peaked at $55K in Q1 2022.
51 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2022.

Based on Caption Management's 13F filing for Q2 2022, filed 15 Aug 2022.